{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:18:35Z","timestamp":1789193915708,"version":"build-2803163510"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T00:00:00Z","timestamp":1413763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim was to evaluate the effect of boceprevir and telaprevir on dolutegravir pharmacokinetics (<jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>); the effect of dolutegravir on boceprevir and telaprevir<jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>was assessed through comparison with historical data for each hepatitis\u2009<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) drug's prescribing information alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010centre, randomized, open\u2010label, two\u2010cohort, two\u2010period, one\u2010way study in healthy adult subjects. Dolutegravir 50\u2009mg once daily was administered for 5 days in Period\u20091, and dolutegravir 50\u2009mg once daily was coadministered with either boceprevir 800\u2009mg every 8\u2009h (Cohort\u20091) or telaprevir 750\u2009mg every 8\u2009h (Cohort\u20092) for 10\u2009days in Period\u20092.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>o deaths or serious adverse events were reported during the study. Four subjects were withdrawn from the study because of adverse events (elevated alanine aminotransferase, cellulitis, increased serum creatinine and dizziness). One subject became pregnant during the study. Coadministration of dolutegravir with boceprevir had no effect on dolutegravir area under the plasma concentration\u2013time curve (<jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>) and maximal plasma concentration (<jats:italic><jats:styled-content style=\"fixed-case\">C<\/jats:styled-content><\/jats:italic><jats:sub>max<\/jats:sub>) and caused a small increase in concentration at the end of the dosing interval (<jats:italic><jats:styled-content style=\"fixed-case\">C<\/jats:styled-content><\/jats:italic><jats:sub>\u03c4<\/jats:sub>; 8%). Coadministration of dolutegravir with telaprevir resulted in increased dolutegravir plasma exposures compared with those after administration of dolutegravir alone;<jats:styled-content style=\"fixed-case\">AUC<jats:sub>0\u2013<\/jats:sub><\/jats:styled-content><jats:sub>\u03c4<\/jats:sub>,<jats:italic><jats:styled-content style=\"fixed-case\">C<\/jats:styled-content><\/jats:italic><jats:sub>max<\/jats:sub>and<jats:italic><jats:styled-content style=\"fixed-case\">C<\/jats:styled-content><\/jats:italic><jats:sub>\u03c4<\/jats:sub>increased by 25, 19 and 37%, respectively. Coadministration of boceprevir or telaprevir with dolutegravir had no clinically significant effect on dolutegravir<jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>. Plasma boceprevir and telaprevir<jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>data for either combined treatment were similar to historical data, indicating no effect of dolutegravir on boceprevir or telaprevir exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dolutegravir can be coadministered with boceprevir or telaprevir in patients coinfected with<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>with no dose adjustment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12428","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T11:11:14Z","timestamp":1400238674000},"page":"1043-1049","source":"Crossref","is-referenced-by-count":16,"title":["Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir"],"prefix":"10.1111","volume":"78","author":[{"given":"Mark","family":"Johnson","sequence":"first","affiliation":[{"name":"R&amp;D Projects and Clinical Platforms GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Borland","sequence":"additional","affiliation":[{"name":"R&amp;D Projects and Clinical Platforms GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Chen","sequence":"additional","affiliation":[{"name":"R&amp;D Projects and Clinical Platforms GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Savina","sequence":"additional","affiliation":[{"name":"R&amp;D Platform Technology and Science GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[{"name":"Clinical Development R&amp;D Infectious Disease GlaxoSmithKline Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Piscitelli","sequence":"additional","affiliation":[{"name":"Clinical Development R&amp;D Infectious Disease GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis750"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00292-13"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0093-2"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318276cda9"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.081906.081110"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-14-22"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31022-1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/751057"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00728-13"},{"key":"e_1_2_9_12_1","unstructured":"Incivek [package insert]. Cambridge MA: Vertex Pharmaceuticals Inc;2013."},{"key":"e_1_2_9_13_1","unstructured":"Victrelis [package insert]. Whitehouse Station NJ: Merck Sharp & Dohme Corp;2014."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1316469"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0022-3565(24)38249-7","article-title":"Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers","volume":"289","author":"Furlan V","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_16_1","unstructured":"Tivicay [package insert]. Research Triangle Park NC: ViiV Healthcare;2013."},{"key":"e_1_2_9_17_1","unstructured":"SongI ChenS PiscitelliS MinS.PK and PK\u2010PD relationship of DTG in INI\u2010naive subjects. Abstract presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotheraphy; September 10\u201313 2013; Denver CO."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048918"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010371113"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70060-9"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12428","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12428","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.12428","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T23:08:01Z","timestamp":1746227281000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,20]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1111\/bcp.12428"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12428","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,20]]}}}